Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Comparing the Use of Renuvion to a Competing Technology Following Liposuction or Body Contouring Procedures
Demonstrates a statistically significant reduction in adverse events associated with the use of Renuvion following liposuction or body contouring, compared to the competing technology
In this retrospective, single-center, contiguous series study, researchers
The researchers analyzed adverse events documented during and post-procedure by body area for both groups. Based on this analysis, they found that the group treated with Renuvion exhibited statistically significant fewer adverse events (p-value <0.0001), compared to the group treated with Bipolar RF. Specifically, 45 adverse events were documented in 34 of the patients treated with Renuvion, compared to 93 adverse events documented in 62 of the patients treated with Bipolar RF. 28 adverse events documented in the Renuvion group were determined to be procedure-related, compared to 69 events in the Bipolar RF group. The researchers found the significantly fewer occurrences of burns, hematoma, hypertrophic scar, and seroma in the Renuvion group to be particularly noteworthy.
Based on these findings, the researchers concluded that Renuvion may offer a safer alternative to Bipolar RF following liposuction or body contouring procedures. They observed that the study’s findings underscore the importance of carefully selecting the appropriate energy-based technology for managing skin laxity following liposuction or body contouring procedures, and added that Renuvion emerges as a promising option over Bipolar RF due to its superior safety profile, shorter procedural times and higher patient satisfaction rates compared to Bipolar RF.
“We are pleased to see the results of this important clinical study published in a peer-reviewed, open access journal, following its presentation at the
A digital version of the clinical publication is available via the following link: Plastic and Reconstructive Surgery – Global Open (lww.com)
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20240808954609/en/
Investor Relations:
ICR Westwicke on behalf of
investor.relations@apyxmedical.com
Source: